Evaluation of a ricin vaccine candidate (RVEc) for human toxicity using an in vitro vascular leak assay

Toxicon

Volumn 58, Issue 1, 2011, Pages 68-75

  Porter, Aimee ^a   Phillips, Gary ^b   Smith, Leonard ^a   Erwin Cohen, Rebecca ^a   Tammariello, Ralph ^a   Hale, Martha ^a   DaSilva, Luis ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Cytotoxicity; Ricin; Ricin vaccine RVEc; Trans endothelial electrical resistance; Vascular leak

Indexed keywords

PROTECTIVE AGENT; RICIN; RICIN A; RICIN B; RICIN VACCINE; RIVAX; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; BIOASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SAFETY; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PRIORITY JOURNAL; TOXICITY TESTING;

AZIDES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; RICIN; TOXICITY TESTS; VACCINES;

ANIMALIA;

EID: 79959374624     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2011.05.005     Document Type: Article

References (23)

1. Baluna R., Coleman E., Jones C., Ghetie V., Vitetta E.S. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp. Cell. Res. 2000, 258:417-424.
2. Baluna R., Rizo J., Gordon B.E., Ghetie V., Vitetta E.V. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. U S A 1999, 96:3957-3962.
3. Baluna R., Vitetta E.S. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997, 37:117-132.
4. Baluna R., Ghetie V., Oppenheimer-Marks N., Vitetta E.S. Fibronectin inhibits the cytotoxic effects of ricin A chain on endothelial cells. Int. J. Immunopharmacol. 1996, 18:355-361.
5. Brogan P.A., Shah V., Klein N., Dillon M.J. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury. Arthritis. Rheum. 2004, 50:589-597.
6. Carra J.H., Wannemacher R.W., Tammariello R.F., Lindsey C.Y., Dinterman R.E., Schokman R.D., Smith L.A. Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. Vaccine 2007 May 22, 25:4149-4158.
7. Dewi B.E., Takasaki T., Kurane I. Peripheral blood mononuclear cells increase the permeability of dengue virus-infected endothelial cells in association with downregulation of vascular endothelial cadherin. J. Gen. Virol. 2008, 89(Pt 3):642-652.
8. Endo Y., Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J. Biol. Chem. 1987, 262:8128-8130.
9. Hughes J., Lindsay C., Griffiths G. Morphology of ricin and abrin exposed endothelial cells is consistent with apoptotic cell death. Hum. Exp. Toxicol. 1996, 15:443-451.
10. Ishida B., Cawley D.B., Reue K., Wisnieski B.J. Lipid protein interactions during ricin toxin insertion into membranes. Evidence for A and B chain penetration. J. Biol. Chem. 1983, 258:5933-5937.
11. Lindstrom A.L., Erlandsen S.L., Kersey J.H., Pennell C.A. An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers. Blood 1997, 90:2323-2334.
12. Maddaloni M., Cooke C., Wilkinson R., Stout A., Eng L., Pincus S. Immunological characteristics associated with the protective efficacy of antibodies to ricin. J. Immunol. 2004, 172:6221-6228.
13. Marsden C.J., SmithRoberts L.M., Lord M.J. Ricin: current understanding and prospects for an antiricin vaccine. Expert Rev. Vaccines 2005, 4:229-237.
14. Marsden C.J., Knight S., Smith D.C., Day P.J., Roberts L.M., Phillips G.J., Lord J.M. Insertional mutagenesis of ricin A chain: a novel route to an anti-ricin vaccine. Vaccine 2004, 22:2800-2805.
15. McGuinness C.R., Mantis N.J. Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit. Infect. Immun. 2006, 74:3463-3470. http://www.ncbi.nlm.nih.gov/pubmed/16714577.
16. McHugh C.A., Tammariello R.F., Millard C.B., Carra J.H. Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein. Sci. 2004, 13:2736-2743.
17. Olson M.A., Carra J.H., Roxas-Duncan V., Wannemacher R.W., Smith L.A., Millard C.B. Finding a new vaccine in the ricin protein fold. Prot. Eng. Design Select. 2004, 17:391-397.
18. Soler-Rodríguez A., Ghetie M., Oppenheimer-Marks N., Uhr J.W., Vitetta E.S. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell. Res. 1993, 206:227-234.
19. Vitetta E.S., Smallshaw J.E., Coleman E., Jafri H., Munford R., Schindler J. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc. Natl. Acad. Sci. U S A 2006, 103:2268-2273.
20. Vitetta E.S., Thorpe P.E., Uhr J.W. Immunotoxins: magic bullets or misguided missiles?. Immunol. Today. 1993, 14:252-259.
21. Warfel J.M., Steele A.D., D'Agnillo F. Anthrax lethal toxin induces endothelial barrier dysfunction. Am. J. Pathol. 2005, 166:1871-1881.
22. Wilhelmsen C.L., Pitt M.L. Lesions of acute inhaled lethal ricin intoxication in rhesus monkeys. Vet. Pathol. 1996, 33:296-302.
23. Yoneyama T., Miyata K., Chikai T., Mikami A., Suzuki T., Hasegawa K., Ikeda T., Watanabe T., Ohyama T., Niwa K., 2008. Clostridium botulinum serotype D neurotoxin and toxin complex bind to bovine aortic endothelial cells via sialic acid. FEMS Immunol. Med. Microbiol. 54, 290-298. [Epub 2008 Sep 17]. http://www.ncbi.nlm.nih.gov/pubmed/18801042.